Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Q3 2023 Earnings Conference Call

November 13, 2023 08:00 AM ET

Company Participants

Alex Braun - Head-IR

Daniel O'Connell - CEO

Eric Siemers - Chief Medical Officer

Matt Zuga - CFO & Chief Business Officer

Conference Call Participants

Thomas Shrader - BTIG

Pete Stavropoulos - Cantor Fitzgerald

Colin Bristow - UBS

Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharma Third Quarter 2023 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference is being recorded.

I will now hand the conference over to your speaker host, Alex Braun, Head of Investor Relations. Please go ahead.

Alex Braun

Thank you, Olivia. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended September 30, 2023. With me today are Dan O'Connell, our Chief Executive Officer; Dr. Eric Siemers, our Chief Medical Officer; and Matt Zuga, our Chief Financial Officer and Chief Business Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning and related slide presentation we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Please see Slide 2 of the accompanying presentation, a press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments.

After our prepared remarks, we'll open the call for Q&A. So now I'll turn the call over to Dan.

Daniel O'Connell

Thanks, Alex. Good morning, and thanks, everyone, for joining us today. Throughout the third quarter and into November, our team is focused on advancing ACU193, our monoclonal antibody for the treatment of early Alzheimer's disease to the next phase of clinical development. We recognize the importance of additional treatment options for Alzheimer's patients and caregivers living with this disease.